Platinum Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Platinum Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-32,300	Closed	-$725K	–	91
2018 Q1	$725K	Hold	32,300	–	–	0.02%	77
2017 Q4	$972K	Hold	32,300	–	–	0.03%	67
2017 Q3	$1.22M	Hold	32,300	–	–	0.03%	61
2017 Q2	$900K	Hold	32,300	–	–	0.02%	63
2017 Q1	$1.11M	Sell	32,300 -6,000	-16%	-$212K	0.03%	63
2016 Q4	$1.1M	Hold	38,300	–	–	0.03%	61
2016 Q3	$1.22M	Hold	38,300	–	–	0.03%	65
2016 Q2	$1.24M	Sell	38,300 -7,700	-17%	-$258K	0.03%	61
2016 Q1	$1.29M	Buy	+46,000	New	+$1M	0.03%	63

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Platinum Investment Management's ACAD Position: Q2 2018 in Review

Platinum Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 32,300 shares — an estimated $725K sold.

Platinum Investment Management first reported a position in ACAD in Q1 2016 and held it in 9 quarters. The position peaked at $1.29M in Q1 2016. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

Platinum Investment Management reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Platinum Investment Management sold 32,300 Acadia Pharmaceuticals shares in Q2 2018, an estimated $725K.
Platinum Investment Management first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Platinum Investment Management's Acadia Pharmaceuticals position peaked at $1.29M in Q1 2016.
187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Platinum Investment Management's 13F filing for Q2 2018, filed 15 Aug 2018.